A quiver of arrows for immune disorders: Pandion scores $80M in fresh funding

The Series B was led by Access Biotechnology, Boxer Capital, RA Capital and OrbiMed and included the participation of Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, JDRF T1D Fund and BioInnovation Capital. The Boston-based startup raised $58 million in January 2018.

Leave a Reply

Your email address will not be published. Required fields are marked *